Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting

Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting

Background: Proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab reduce ischemic events; however, the cost-effectiveness remains uncertain. This study sought to evaluate its economic value in patients with myocardial infarction (MI) from the Chinese healthcare perspective.Methods: A st...

Full description

Bibliographic Details
Main Authors: Zhe Liang, Qi Chen, Ruiqi Wei, Chenyao Ma, Xuehui Zhang, Xue Chen, Fang Fang, Quanming Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Pharmacology
Subjects:
alirocumab
cost-effectiveness
myocardial infarction
PCSK9 inhibitors
secondary prevention
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.648244/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.648244/full

Similar Items